Mega Lifesciences 관리

관리 기준 확인 2/4

Mega Lifesciences CEO는 Vivek Dhawan, Jan1988 에 임명되었습니다 의 임기는 36.83 년입니다. 는 THB 2.04B 가치에 해당하는 회사 주식의 6.59% 직접 소유합니다. 2.04B. 경영진과 이사회의 평균 재임 기간은 각각 26.8 년과 11.8 년입니다.

주요 정보

Vivek Dhawan

최고 경영자

n/a

총 보상

CEO 급여 비율	n/a
CEO 임기	36.8yrs
CEO 소유권	6.6%
경영진 평균 재임 기간	26.8yrs
이사회 평균 재임 기간	11.8yrs

최근 관리 업데이트

Recent updates

CEO

Vivek Dhawan (63 yo)

36.8yrs

테뉴어

Mr. Vivek Dhawan is CEO, Chief Coach & Executive Director of Mega Lifesciences Public Company Limited from 2013. He joined the Mega Lifesciences Public Company Limited in 1986. He is CEO & Chief Coach of M...

리더십 팀

이름	위치	테뉴어	보상	소유권
Vivek Dhawan	CEO, Chief Coach & Executive Director	36.8yrs	데이터 없음	6.59% THB 2.0b
Thomas Abraham	CFO & Executive Director	26.8yrs	데이터 없음	0.76% THB 236.7m
Deepak Panjwani	Chief Risk & Compliance Officer	no data	데이터 없음	데이터 없음
Paramjit Sawhney	President of International	no data	데이터 없음	1.5% THB 464.5m
Girish Wadhwa	President of Myanmar	no data	데이터 없음	데이터 없음
Manoj Gurbuxani	Deputy Chief Financial Officer	4.8yrs	데이터 없음	0.000010% THB 3.1k
Duangnapa Tongsiri	President of Mega We Care Thailand	no data	데이터 없음	1.48% THB 457.3m
Sujintana Boonworapat	Corporate Secretary	no data	데이터 없음	0.019% THB 6.0m

26.8yrs

평균 재임 기간

57.5yo

평균 연령

경험이 풍부한 관리: MEGA 의 관리팀은 노련하고 경험 (평균 재직 기간 26.8 년)입니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Vivek Dhawan	CEO, Chief Coach & Executive Director	11.8yrs	데이터 없음	6.59% THB 2.0b
Thomas Abraham	CFO & Executive Director	26.8yrs	데이터 없음	0.76% THB 236.7m
Yim Chi	Independent Vice Chairma	11.8yrs	฿1.58m	데이터 없음
Kirit Chimanlal Shah	Non-Executive Director	11.8yrs	฿661.50k	49.81% THB 15.4b
Shiraz Poonevala	Non-Executive Director	11.8yrs	฿661.50k	데이터 없음
Ishaan Shah	Non-Executive Director	11.8yrs	฿661.50k	0.32% THB 98.9m
Mechai Viravaidya	Independent Chairman	11.8yrs	฿2.21m	데이터 없음
Sameera Shah	Non-Executive Director	11.8yrs	฿661.50k	데이터 없음
Thor Santhisiri	Independent Director	11.8yrs	฿1.15m	0.022% THB 6.7m
Vijay Karwal	Independent Director	3.5yrs	฿1.15m	데이터 없음
Nithinart Sinthudeacha	Independent Director	1.8yrs	฿1.15m	데이터 없음

11.8yrs

평균 재임 기간

62yo

평균 연령

경험이 풍부한 이사회: MEGA 의 이사회는 노련하고 경험이 있습니다(평균 재직 기간 11.8 년).

Mega Lifesciences 관리

관리 기준 확인 2/4

주요 정보

최근 관리 업데이트

Less than half of directors are independent

Less than half of directors are independent

Mega Lifesciences Public Company Limited Appoints Alan Kam to Be the Vice Chairman of the Board of Directors

Mega Lifesciences Public Company Limited, Annual General Meeting, Apr 05, 2022

Mega Lifesciences Public Company Limited, Annual General Meeting, Apr 05, 2021

Recent updates

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

First half dividend of ฿0.80 announced

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

First quarter 2024 earnings released: EPS: ฿0.55 (vs ฿0.52 in 1Q 2023)

Upcoming dividend of ฿0.80 per share

Final dividend reduced to ฿0.80

Mega Lifesciences Public Company Limited Proposes Dividend for the Year Ended December 31, 2023, Payable on April 22, 2024

Full year 2023 earnings released: EPS: ฿2.29 (vs ฿2.57 in FY 2022)

Now 20% undervalued

Mega Lifesciences Public Company Limited to Report Q3, 2024 Results on Nov 12, 2024

Third quarter 2023 earnings: EPS misses analyst expectations

Now 21% undervalued

Now 21% undervalued

Upcoming dividend of ฿0.80 per share at 3.8% yield

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Mega Lifesciences Public Company Limited Announces Cash Dividend for the Period from January 1, 2023to June 30, 2023, Payable on September 8, 2023

Now 20% undervalued after recent price drop

Mega Lifesciences Public Company Limited to Report Q2, 2023 Results on Aug 11, 2023

Now 25% undervalued after recent price drop

First quarter 2023 earnings: EPS misses analyst expectations

Now 22% undervalued after recent price drop

Upcoming dividend of ฿0.85 per share at 3.5% yield

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Less than half of directors are independent

Now 21% undervalued after recent price drop

Upcoming dividend of ฿0.75 per share

Second quarter 2022 earnings: Revenues exceed analyst expectations

Mega Lifesciences Public Company Limited Announces Cash Dividend for the Period from January 1, 2022 to June 30, 2022, Payable on September 9, 2022

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Less than half of directors are independent

Mega Lifesciences Public Company Limited Appoints Alan Kam to Be the Vice Chairman of the Board of Directors

Upcoming dividend of ฿0.86 per share

Mega Lifesciences Public Company Limited, Annual General Meeting, Apr 05, 2022

Mega Lifesciences Public Company Limited Proposes Dividend for Year Ended December 31, 2021, Payable on April 22, 2022

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Now 21% undervalued

Investor sentiment improved over the past week

Third quarter 2021 earnings released: EPS ฿0.70 (vs ฿0.39 in 3Q 2020)

Investor sentiment improved over the past week

Upcoming dividend of ฿0.52 per share

Second quarter 2021 earnings released: EPS ฿0.58 (vs ฿0.35 in 2Q 2020)

First quarter 2021 earnings released: EPS ฿0.38 (vs ฿0.37 in 1Q 2020)

New 90-day low: ฿35.50

Mega Lifesciences Public Company Limited, Annual General Meeting, Apr 05, 2021

Revenue and earnings beat expectations

Full year 2020 earnings released: EPS ฿1.60 (vs ฿1.31 in FY 2019)

New 90-day high: ฿40.50

New 90-day high: ฿39.00

Third quarter 2020 earnings released: EPS ฿0.39

Revenue and earnings beat expectations

New 90-day low: ฿32.00

New 90-day low: ฿33.00

Mega Lifesciences Public Company Limited (SET:MEGA) completed the acquisition of 83.33% stake in PT Futamed Pharmaceuticals from PT Ersons and others for approximately IDR 180 billion.

CEO

테뉴어

리더십 팀

평균 재임 기간

평균 연령

이사회 구성원

평균 재임 기간

평균 연령